Fennec Pharmaceuticals (TSE:FRX) Insider Pierre Sayad Sells 12,000 Shares

Fennec Pharmaceuticals Inc. (TSE:FRX) insider Pierre Sayad sold 12,000 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of C$17.18, for a total value of C$206,160.00. Following the completion of the sale, the insider directly owned 9,519 shares of the company’s stock, valued at C$163,536.42. The trade was a 55.76% decrease in their ownership of the stock.

Fennec Pharmaceuticals Stock Down 1.8%

TSE:FRX opened at C$17.10 on Wednesday. The stock’s 50 day moving average price is C$15.52 and its 200 day moving average price is C$12.66. The company has a market capitalization of C$599.65 million, a PE ratio of -142.50 and a beta of 3.72. Fennec Pharmaceuticals Inc. has a 52-week low of C$7.59 and a 52-week high of C$17.64.

Institutional Trading of Fennec Pharmaceuticals

A hedge fund recently bought a new stake in Fennec Pharmaceuticals stock. Cornerstone Capital Inc. purchased a new stake in Fennec Pharmaceuticals Inc. (TSE:FRX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 105,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,129,000. Cornerstone Capital Inc. owned about 0.30% of Fennec Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.40% of the company’s stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.